Xenoestrogens earn their name from their structural resemblance to endogenous estrogens, the natural hormones that guide far more than reproduction. In the brain, estrogen signaling shapes neuronal differentiation, synaptic plasticity, neurotransmitter release, and the organization of sexually dimorphic circuits. Because xenoestrogens can bind estrogen receptors and hijack these pathways, they can mimic, amplify, or scramble hormonal instructions at concentrations far below those traditionally used in toxicological testing. The review emphasizes that these compounds frequently display non-monotonic dose-response curves, meaning that low doses can produce effects that are different, or even opposite, to those seen at high doses. That property upends a foundational assumption of classical toxicology, which has long held that the dose makes the poison.

The chemicals in question are everywhere. Bisphenol A, or BPA, leaches from plastic containers, food-can linings, and thermal receipts. Phthalates, added to plastics to make them flexible and durable, shed from personal care products, building materials, and countless household items. Polychlorinated biphenyls, or PCBs, were banned decades ago yet persist in soil, water, and animal tissue, bioaccumulating as they move up the food chain. Natural xenoestrogens such as phytoestrogens, found in certain plants, add a further layer of complexity. The result, the authors note, is chronic, low-dose, real-world exposure to a shifting cocktail of compounds whose combined effects remain poorly understood.

At the molecular level, the review describes several converging mechanisms of harm. BPA and certain PCBs bind estrogen receptors ERα and ERβ, triggering both genomic and rapid non-genomic signaling through pathways such as MAPK and PI3K/AKT, which govern cell proliferation, apoptosis, and differentiation. Xenoestrogens also disrupt the synthesis, transport, and metabolism of endogenous hormones by interfering with the hypothalamic-pituitary-gonadal axis, tilting the hormonal milieu that the developing brain depends on. Beyond receptor binding, these compounds perturb calcium signaling and glutamatergic neurotransmission by modulating NMDA receptor expression, a shift that can push neurons toward excitotoxicity and impair the precise wiring of synaptic connections.

Perhaps the most unsettling mechanism is epigenetic. Xenoestrogen exposure can induce aberrant DNA methylation and histone modifications, chemically rewriting the instructions that govern gene expression without changing the underlying DNA sequence. Among the genes affected are BDNF, SHANK3, and RELN, all of which are central to synaptic function and have been implicated in neurodevelopmental disorders such as autism spectrum disorder and attention-deficit/hyperactivity disorder. The downstream consequences include defects in synaptic pruning, neuronal migration, and myelination, the very processes that sculpt a mature, functional brain. Because epigenetic marks can be inherited, the review raises the possibility that today’s exposures may predispose future generations to neurodevelopmental vulnerability, a transgenerational shadow that conventional risk assessments have barely begun to address.

The behavioral evidence spans the laboratory and the wild. In rodent models, perinatal exposure to BPA, PCBs, and the synthetic estrogen diethylstilbestrol disrupts mating behavior by deranging the hypothalamic-pituitary-gonadal axis and altering estrogen and testosterone levels. Male rodents exposed to BPA early in life show reduced mounting and intromission frequencies, while females display altered estrous cyclicity and diminished lordosis responses. The sexually dimorphic nucleus of the preoptic area, normally larger in males, shrinks following early-life exposure to estrogenic disruptors, accompanied by disturbances in dopamine and oxytocin signaling that underpin sexual and affiliative behavior. In aquatic species, estrogenic pollutants have feminized male fish and amphibians, collapsing courtship behavior and reproductive success, with one landmark study documenting the collapse of an entire fish population after exposure to a synthetic estrogen.

Cognitive and emotional effects are equally well documented. The review links xenoestrogen exposure to impairments in learning, memory, and executive function, with implications for academic and professional performance, and to heightened anxiety, depression, and mood dysregulation, likely reflecting disruption of the limbic system. Social behavior is also affected, with altered social recognition, interaction, and communication observed across studies. Critically, many of these effects are sex-specific. Estrogen receptor subtypes are distributed differently in male and female brains, particularly in the hypothalamus, hippocampus, and amygdala, and male neurodevelopment depends heavily on the aromatization of testosterone into estradiol, creating distinct points of vulnerability. Prenatal BPA exposure, for example, has been associated with hypomethylation of the estrogen receptor alpha gene in the prefrontal cortex of female rodents but not males, correlating with increased anxiety-like behavior in females. The authors call for sex-stratified analyses to become standard practice in this field.

Timing magnifies the danger. The developing brain passes through tightly choreographed windows, spanning prenatal life, infancy, early childhood, and adolescence, when hormonal signals orchestrate the construction of neural circuits. Exposure during these periods can permanently alter brain structure, neuronal connectivity, and neurotransmitter systems, and the review links prenatal and early-childhood exposures to neurodevelopmental disorders, cognitive deficits, and behavioral abnormalities that persist into adulthood. Fetuses and infants are especially susceptible because their detoxification systems are immature and their brains are maximally plastic, while adolescents face risks during the extensive cortical reorganization of that stage. Regulatory frameworks, the authors argue, have lagged badly behind the science. Agencies such as the United States Food and Drug Administration and Environmental Protection Agency have restricted some compounds, and the European Union and World Health Organization have taken steps of their own, but critics contend these measures are insufficient. Most regulations still test chemicals one at a time and at high doses, missing the low-dose and mixture effects that define real-world exposure, and industry-conducted safety assessments raise conflicts of interest. The pattern of regrettable substitution is a case in point: when BPA was phased out, structurally similar analogs such as BPS and BPF moved in, potentially carrying comparable endocrine-disrupting activity. Legacy pollutants like DDT and PCBs continue to circulate decades after their bans.

What can be done? The review outlines a prevention agenda that spans individual action and structural reform. Reducing exposure means choosing products free of known xenoestrogens, improving manufacturing practices, and strengthening waste management. Public education can empower families, clinicians, and policymakers to make informed choices, while targeted interventions, including dietary modifications and environmental remediation, may help protect the most vulnerable. On the research frontier, the authors identify priorities that include characterizing emerging xenoestrogens, deploying sensitive tools such as neuroimaging and epigenetic profiling, testing whether pharmacological or nutritional therapies can mitigate harm, and untangling the synergistic effects of chemical mixtures. They also flag persistent methodological hurdles: non-monotonic dose responses that defy standard modeling, species differences that complicate extrapolation to humans, and the difficulty of sustaining longitudinal studies long enough to capture chronic and transgenerational outcomes. The bottom line, the authors conclude, is that safeguarding the neurological health of current and future generations demands a coordinated, precautionary response, one that combines rigorous independent research, evidence-based policymaking, international collaboration, and honest public engagement with the invisible chemical landscape that now surrounds every developing brain.

Subject of Research: Neurobehavioral and developmental toxicity caused by xenoestrogen endocrine-disrupting chemicals

Article Title: An overview of neurobehavioral and developmental toxicity induced by xenoestrogens

Article References: Shaw, R., Kamath, A. S., & Chaube, R. (2025). An overview of neurobehavioral and developmental toxicity induced by xenoestrogens. Discover Toxicology, 2(1), Article 10. https://doi.org/10.1007/s44339-025-00025-x

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00025-x

Keywords: xenoestrogens, endocrine-disrupting chemicals, bisphenol A, phthalates, PCBs, estrogen receptors, neurodevelopment, epigenetics, developmental toxicity, neurobehavioral effects, brain development, public health

The core of the problem lies in molecular mimicry. BPA’s structure bears a striking resemblance to steroidal estrogens such as diethylstilbestrol, allowing it to bind to estrogen receptors and exert estrogen-like effects in tissues ranging from the uterus and mammary glands to the brain and cardiovascular system. The review emphasizes that BPA binds to the estrogen receptor with an affinity roughly one thousand-fold lower than estradiol itself, which sounds reassuring until one considers the concentrations achieved in blood after a meal consumed from BPA-lined packaging. Crucially, the compound does not limit itself to estrogen receptors. It also interacts with androgen receptors, thyroid hormone receptors, glucocorticoid receptors, and the aryl hydrocarbon receptor, meaning that a single molecule can perturb multiple hormonal axes simultaneously, disrupting the synthesis, secretion, transport, metabolism, binding, and elimination of the body’s own hormones.

Perhaps the most technically significant advance highlighted in the review is the recognition that BPA’s actions extend far beyond the classical genomic pathway, in which a ligand enters the nucleus and alters gene transcription over hours. Recent mechanistic work shows that BPA also engages the G protein-coupled estrogen receptor, known as GPER, located on the cell membrane. Activation of GPER triggers rapid, non-genomic signaling cascades, including the cAMP/PKA pathway, PLC-mediated PKC activation, and transactivation of the epidermal growth factor receptor with downstream MAPK/ERK signaling. These membrane-initiated events have been implicated in altered immune signaling, with reduced interleukin-10 and interleukin-13 secretion observed in human immune cells, as well as in the promotion of cancer cell migration and invasiveness. Researchers argue that this rapid signaling mode helps explain the sometimes non-monotonic responses to BPA, in which low doses produce effects that higher doses do not, and they recommend that GPER engagement be explicitly considered when evaluating the safety of BPA substitutes.

That non-monotonic dose-response relationship strikes at the heart of conventional toxicology. Traditional risk assessment assumes that harm increases with dose, yet studies compiled in the review show measurable biological changes at doses within the range of everyday human exposure, levels often below those used in classic high-dose studies. In mice, in utero exposure to BPA reduced spine densities in the hippocampal CA1 region regardless of the dose administered to the mother, and the disruption of neuronal morphology persisted into adulthood. Such findings suggest that the developing brain, where hormones orchestrate neuronal differentiation, synapse formation, and overall cortical organization, is exquisitely vulnerable during critical windows of development. Exposure during these periods can produce long-lasting neurodevelopmental and behavioral deficits, including altered social behavior, anxiety, and changes in maternal behavior, effects documented across rodent models and zebrafish larvae, where BPA treatment decreased spontaneous movement and dysregulated genes associated with neurological system processes.

The epigenetic dimension adds an even more provocative layer. BPA exposure has been shown to alter DNA methylation patterns, the chemical tags that regulate gene expression without changing the underlying genetic code. Because epigenetic marks can be inherited through cell division and, in some cases, across generations, these modifications raise the possibility that today’s exposure could influence the health of descendants not yet born. Early-life exposure to endocrine disruptors has been associated with epigenetic reprogramming that manifests as increased disease risk later in life, a mechanism that may link prenatal BPA exposure to altered sexual differentiation, reduced fertility, and heightened susceptibility to reproductive cancers observed in animal models.

Sex differences emerge as a recurring theme throughout the evidence. Male, but not female, juvenile rats showed a noticeable decline in spatial memory following exposure to 0.4 milligrams per kilogram per day of BPA, while female offspring of mothers exposed to low doses were significantly heavier than controls or offspring exposed to high doses. Thyroid function tells a similarly paradoxical story: pooled analyses and recent cohort reports indicate that higher BPA concentrations are associated with lower free thyroxine and lower thyroid-stimulating hormone in males, whereas in females BPA is more often associated with higher free thyroxine, with TSH associations less consistent. The review attributes these divergent patterns to BPA’s multi-modal actions, including anti-androgenic effects and interference with thyroid hormone biosynthesis in males, and estrogenic modulation of thyroid hormone-binding proteins and peripheral deiodination in females.

Reproductive health bears the brunt of BPA’s interference in both sexes. In females, exposure disrupts the hypothalamic-pituitary-ovarian axis, interfering with gonadotropin-releasing hormone, luteinizing hormone, and follicle-stimulating hormone, pathways essential for ovulation and menstrual cycle regulation. BPA can also stimulate aromatase, the enzyme that converts androgens into estrogens, elevating estrogen levels and potentially promoting estrogen-dependent conditions such as endometriosis, uterine fibroids, and breast cancer, while simultaneously blocking progesterone signaling, a disruption linked to increased risks of miscarriage and preterm labor. In males, BPA disrupts the hypothalamic-pituitary-testicular axis, reduces the number and viability of testosterone-producing Leydig cells, and interferes with androgen receptor signaling, outcomes associated with reduced sperm production, impaired sperm motility, and altered luteinizing hormone levels that may reflect compensatory responses to falling testosterone.

The metabolic consequences may be equally consequential. Epidemiological studies suggest an association between high urinary BPA levels and predisposition to obesity, and animal experiments show that BPA promotes adipogenesis, increases fat accumulation, and disrupts glucose metabolism. Mechanistically, receptor-level endocrine disruption activates adipogenic transcriptional programs driven by PPARγ and C/EBPα, increases lipid accumulation and inflammatory signaling in adipose tissue, and impairs insulin signaling, providing a plausible pathway from plasticizer to metabolic syndrome. BPA can reduce cellular sensitivity to insulin by interfering with insulin receptor signaling, and may lower adiponectin, the hormone that helps regulate glucose and lipid metabolism. Recent work in mice even implicates gut microbiota-dependent bile acid metabolism and TGR5/UCP1 signaling in BPA-driven fat gain, with epigenetic reprogramming acting as an amplifying mediator.

Against this backdrop, the regulatory landscape remains fragmented and, in the view of the review’s authors, insufficient. The European Union, Canada, and China have banned BPA in baby bottles, the United States has restricted it in baby bottles and sippy cups, and California has imposed labeling requirements, yet the FDA has not banned BPA from all food and beverage containers and continues to monitor the evidence. Meanwhile, more than one hundred tons of BPA are discharged into the environment annually, leaching from containers into food, escaping from landfills and sewage treatment plants, and contaminating air, water, soil, and sediment. The industry’s pivot to substitutes, chiefly bisphenol S and bisphenol F, now common in thermal paper receipts, has not resolved safety concerns, as studies indicate these analogues may exert endocrine-disrupting effects similar to BPA’s. The review concludes that comprehensive toxicological evaluation of alternatives, transparent evidence-based policy, public education, improved labeling, and innovation in genuinely safer materials are urgently needed, because the evidence now shows that harm can occur at exposure levels people encounter every single day.

Subject of Research: Endocrine-disrupting effects of bisphenol A on human hormone systems and health outcomes

Article Title: Effects of Bisphenol-A on human endocrine function and health outcomes: a review

Article References: Effects of Bisphenol-A on human endocrine function and health outcomes: a review. (n.d.). https://doi.org/10.1007/s44339-025-00046-6

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00046-6

Keywords: bisphenol A, endocrine disruptors, estrogen receptors, GPER, thyroid hormones, obesity, insulin resistance, reproductive health, epigenetics, brain development, BPS, BPF